Mitochondrial fission and fusion in inflammatory diseases: mechanisms and therapeutic implications Authors: Wenjing Xu, Xinru Xu, Yaonan Zhang, Fenfen Li, Daozong Xia Published: 2025 ABSTRACT AbstractBackgroundMitochondrial fission and fusion are dynamic and highly regulated processes that are essential for maintaining cellular homeostasis. These processes are regulated by core proteins, including dynamin-related protein 1 (DRP1), fission 1 protein (FIS1), mitochondrial fission factor (MFF), mitofusin 1 (MFN1), mitofusin 2 (MFN2), and optic atrophy 1 (OPA1), which ensure proper mitochondrial function and integrity.Main bodyAn imbalance in fission and fusion can lead to excessive production of ROS, mtDNA release, and alterations in immune cell phenotypes. These disruptions compromise mitochondrial integrity, redox balance, and metabolic adaptability, ultimately activating inflammatory signaling pathways and triggering immune dysregulation. Restoring mitochondrial dynamics has emerged as a promising therapeutic strategy to mitigate these disruptions. A growing number of evidence indicates that small-molecule modulators, natural compounds, genetic interventions, chemical drugs, and mitochondria-targeted nanoformulations hold great potential for re-establishing mitochondrial homeostasis and suppressing inflammation. This review systematically elucidates the molecular mechanisms by which mitochondrial fission and fusion regulate inflammation, summarizes current therapeutic advances, and discusses translational perspectives and future challenges in this rapidly evolving field.ConclusionsModulating mitochondrial dynamics is a promising therapeutic strategy for inflammation, but its clinical translation still faces many challenges. Future research should focus on optimizing mitochondrial dynamic modulation strategies and evaluating their long-term efficacy and safety.Keywords: Mitochondrial dynamics, Inflammatory diseases, Inflammatory pathways, Therapeutic targets, Translational medicine Introduction Mitochondria are ubiquitous organelles in eukaryotic cells. Beyond their role as the cellular powerhouse for ATP production, mitochondria act as central hubs for cellular metabolism and redox balance, and serve as platforms for numerous signaling pathways that maintain cellular homeostasis. Mitochondria are enclosed by a double-membrane system consisting of the outer mitochondrial membrane (OMM), the intermembrane space (IMS) that lies between the two membranes, and the inner mitochondrial membrane (IMM). The OMM contains channels such as voltage-dependent anion channels (VDACs) that regulate the selective exchange of metabolites and proteins, serves as a scaffold for signaling complexes, participate in inter-organelle contacts, and contributes to mitochondrial quality control. The IMM is extensively folded into cristae, which harbor the electron transport chain (ETC) complexes and ATP synthase, providing the structural basis for oxidative phosphorylation (OXPHOS) [1–3]. Mitochondrial plasticity, mediated by coordinated fission and fusion events, enables rapid remodeling of organelle morphology and function in response to metabolic demands and stress signals, thereby positioning mitochondria as pivotal regulators of inflammation and immune signaling [4, 5]. These morphological transitions are orchestrated by conserved dynamin family GTPases. Dynamin-related protein 1 (DRP1) mediates fission by assembling at OMM constriction sites through interactions with receptor proteins, whereas mitofusins (MFN1/2) mediate OMM fusion and optic atrophy protein 1 (OPA1) regulates IMM fusion and cristae remodeling [6, 7]. Importantly, beyond preserving organelle integrity, dysregulation of mitochondrial dynamics directly impacts inflammatory signaling [8]. Excessive fission promotes mitochondrial fragmentation and the release of damage-associated molecular patterns (DAMPs), including mtDNA and mtROS, which can activate innate immune pathways such as the NLRP3 inflammasome and the cGAS-STING pathway. Conversely, impaired fusion compromises mitochondrial bioenergetics and stress adaptation, thereby exacerbating pro-inflammatory signaling [9]. Although pharmacological modulators of fission and fusion have shown promising anti-inflammatory efficacy in preclinical models, their safety, specificity, and efficacy in humans remain to be established [10–12]. This review highlights the role of mitochondrial fission and fusion in the pathogenesis of inflammatory diseases, discusses how their dynamic balance shapes inflammatory signaling, and summarizes recent advances in therapeutic modulators that restore mitochondrial dynamics. By linking molecular mechanisms to translational opportunities, we aim to advance the development of mitochondria-targeted anti-inflammatory therapies. Molecular mechanisms and functional roles of mitochondrial fission and fusion Mitochondrial dynamics are governed by a precisely coordinated balance between fission and fusion, which continuously remodels the mitochondrial network to meet the bioenergetic and biosynthetic demands of the cell. These opposing yet interdependent processes are executed by a set of large dynamin-related GTPases that control OMM and IMM remodeling (Fig. 1). Fission promotes mitochondrial division and quality control, whereas fusion ensures the maintenance of mitochondrial integrity and metabolic efficiency [13]. Dysregulation of either process results in structural fragmentation or hyperfusion, leading to bioenergetic collapse, oxidative stress, and impaired cellular homeostasis. Schematic representation of mitochondrial fission and fusion dynamics. Mitochondrial fission sites are frequently marked by ER-mitochondria contact points, which induce preconstriction of the mitochondrial membrane and facilitate the recruitment of the cytosolic GTPase DRP1 via OMM receptor/adapter proteins such as FIS1, MFF, MiD49/MiD51. Subsequently, DRP1 oligomerizes on the OMM to form helical structures and utilizes the energy from GTP hydrolysis to constrict and divide mitochondria. Mitochondrial fusion depends on the coordinated activity of GTPases located in both the OMM and the IMM. MFN1 and MFN2 on the OMM mediate outer membrane tethering and fusion between adjacent mitochondria through GTP hydrolysis, whereas OPA1 on the IMM promotes inner membrane fusion through the concerted action of its long and short isoforms Mitochondrial fission machinery In mammals, mitochondrial fission is primarily regulated by DRP1 and its OMM receptor proteins. Fission initiates with preconstriction of mitochondria by the endoplasmic reticulum (ER) and microtubules. Subsequently, DRP1 is recruited to the OMM by receptor proteins such as FIS1, MFF, MiD49, and MiD51, where it assembles into helical oligomers. Ultimately, GTP hydrolysis drives membrane scission, completing fission [6, 14–16]. Structure and regulation of DRP1 DRP1 is a crucial regulator of mitochondrial fission. It consists of four domains, the GTPase domain, the middle domain, the variable domain, and the GTPase effector domain [17, 18]. Based on this structural framework, DRP1 activation and mitochondrial recruitment are tightly regulated by multiple signaling pathways, which often act through post-translational modifications (PTMs) to modulate its conformation and activity [19]. Among these PTMs, phosphorylation is the most widely studied. Phosphorylation at Ser616 (catalyzed by kinases such as CDK1, ERK1/2 or ROCK1) activates fission, while phosphorylation at Ser637 (catalyzed by PKA or mediated by calcineurin) inhibits this process [20–24]. However, this regulation is not fixed, but depends on the cellular metabolic state and upstream signals. Other regulatory mechanisms include SUMOylation, ubiquitination, and S-nitrosylation, all of which can control the stability, localization, and fission capacity of DRP1 in response to stress and metabolic signals [25–28]. Structure and regulation of FIS1 and MFF FIS1 was the first identified DRP1 adaptor protein, and its N-terminal tetratricopeptide repeat-like domain provides docking sites for the variable region of DRP1, thereby ensuring spatial precision in fission site selection [29]. Interestingly, MFF and FIS1 share similar structural features. The N-terminal cytoplasmic domain of MFF can directly bind to DRP1, promoting DRP1 oligomerization and assembly at the fission site [14]. Other adaptor proteins, such as MiD49 and MiD51, act synergistically with or complement FIS1/MFF to precisely regulate DRP1 recruitment [30, 31]. Notably, the ER and actin cytoskeleton also participate in preconstriction, ensuring that DRP1-mediated fission occurs at precisely defined sites [32]. These multifaceted regulatory mechanisms collectively determine the extent and physiological outcomes of mitochondrial fission. Functional implications of mitochondrial fission Mitochondrial fission plays a pivotal role in sustaining metabolic flexibility and mitochondrial quality. Moderate fission increases mitochondrial numbers to meet rising energy demands, whereas excessive fragmentation disrupts the membrane potential, impairs OXPHOS, and leads to ATP depletion [33–35]. Beyond energy metabolism, DRP1-mediated fission is also a core checkpoint in apoptosis. DRP1 translocation to mitochondria enhances Bax/Bak oligomerization, facilitating OMM permeabilization and cytochrome c release, thereby enhancing mitochondria-dependent apoptosis [36]. Fission also coordinates with selective mitophagy to eliminate dysfunctional mitochondria. Studies showed that the interaction between DRP1 and the mitochondrial zinc transporter Zip1 triggers Zn2 + influx into the mitochondrial matrix, leading to transient mitochondrial depolarization and subsequently facilitating Parkin- or Arih1-dependent mitophagy, thereby achieving mitochondrial quality surveillance [37]. Mitochondrial fusion machinery Mitochondrial fusion is mediated by GTPases MFN1/2 and OPA1, maintaining integrity and homeostasis of the mitochondrial network. This process occurs in a stepwise manner. First, mitochondrial phospholipase D hydrolyzes cardiolipin to generate phosphatidic acid, inducing membrane curvature. Next, OMM-localized proteins MFN1 and MFN2 mediate tethering of adjacent mitochondria, forming homo- and hetero-dimeric complexes at contact sites. The formation of these complexes triggers GTP hydrolysis, inducing conformational changes and generating mechanical forces that drive OMM fusion. Following this, the IMM-anchored GTPase OPA1 regulates cristae remodeling through proteolytic processing and GTP-dependent conformational changes, ultimately completing IMM fusion [38–40]. MFN1/2-mediated OMM fusion Recent structural analyses have refined the topology of MFN1 and MFN2, confirming that they are single-spanning OMM proteins with their C-termini extending into the IMS. Redox-sensitive cysteine residues in this region can form intermolecular disulfide bonds, driving the trans-oligomerization of Mfns to promote membrane fusion [41]. Despite their structural similarity, MFN1 and MFN2 exhibit significant differences in their biochemical activities and physiological functions [42–44]. MFN1 possesses higher GTPase activity, primarily relying on dimerization of its own GTPase domains to efficiently drive membrane binding and fusion [45]. In contrast, MFN2 exhibits lower GTPase activity and is more regulated by external partners and enzymes [46, 47]. In addition to mediating OMM fusion, MFN2 specifically participates in the formation of mitochondrial-associated endoplasmic reticulum membranes, further regulating Ca+ transport, lipid exchange, and energy signaling [48, 49]. At the molecular level, the activity and stability of MFN1/2 are regulated by a complex network of PTMs. Under metabolic stress, acetylation of MFN2 at K243 induces its ubiquitin-proteasome degradation, disrupting mitochondrial-lipid droplet contacts and inducing myocardial lipotoxicity [50]. Furthermore, Poly (ADP-ribose) polymerase family member 12-mediated ISGylation inhibits MFN1/2 ubiquitination and SUMOylation, thereby blocking PINK1/Parkin-dependent mitophagy and indirectly disrupting fusion balance [51]. Notably, phosphorylation of MFN2 at the same residue can produce opposite effects, suggesting that its function may be regulated by upstream kinases [52, 53]. In brief, these studies highlight the dynamic and context-dependent regulation of MFN1/2 by PTMs, though how distinct modifications coordinate to shape Mfns conformation and complex assembly remains to be clarified. OPA1-dependent IMM fusion OPA1 is a dynamin-related GTPase localized to the IMM that mediates IMM fusion and maintains cristae structure. OPA1 exists in two isoforms: L-OPA1, which has a transmembrane domain anchoring the protein to the IMM, and soluble S-OPA1, resulting from proteolytic cleavage of L-OPA1 in the IMS [54]. Under physiological conditions, L-OPA1 and S-OPA1 maintain a certain proportion and synergistically regulate IMM fusion. However, under pathological stress, L-OPA1 is predominantly converted to S-OPA1, leading to reduced fusion efficiency and promoting mitochondrial fragmentation [55]. In addition to classical proteolytic processing, OPA1 activity is likewise shaped by PTMs such as acetylation and ubiquitination, which provide new targets for intervention in related diseases. For example, the mitochondrial deacetylase SIRT3 can directly or indirectly deacetylate OPA1, enhancing its GTPase activity and promoting mitochondrial fusion, thereby resisting stress and maintaining homeostasis [56–59]. More importantly, the bidirectional regulation of OPA1 stability by ubiquitination is particularly prominent in diabetic complications. Studies in models of diabetic cardiomyopathy have showed that PFKFB3 recruits NEDD4L to mediate protective K6-linked ubiquitination of OPA1, thereby preventing its degradation and improving cardiac function [60]. Conversely, research on diabetic nephropathy revealed that overexpressed TRIM22 promotes the destructive ubiquitination and degradation of OPA1, exacerbating renal damage [60, 61]. These findings not only reveal the complexity of OPA1 regulation but also put the SIRT3-OPA1 axis and the ubiquitination pathway at the forefront of drug development for diabetes and its complications. Functional implications of mitochondrial fusion Mitochondrial fusion is fundamental for maintaining network integrity and cristae structure, which in turn underlies efficient energy metabolism. This is evidenced by studies showing that loss of fusion proteins (MFN2 or OPA1) impairs cristae architecture and ETC efficiency, and knockdown of MFN1 and OPA1 in aged normal human fibroblasts reduces oxygen consumption and shifts cellular metabolism toward glycolysis [62–64]. Importantly, the relationship between fusion and function is not linear. Supporting this notion, although MFN1 overexpression enhances mitochondrial network connectivity, the resulting hyperfusion leads to metabolic imbalance, increased oxidative stress, and ETC dysfunction [65]. From this, we can conclude that the maintaining mitochondrial function requires a balance between fission and fusion, not the regulation of just one. Mitochondrial fusion also participates in cell differentiation and fate determination. During the differentiation of mesenchymal stem cells into adipocytes or osteocytes, the levels of MFN1 and MFN2 increase, promoting the formation of an interconnected mitochondrial network [66, 67]. Similarly, in spermatogonial differentiation, enhanced fusion contributes to differentiation progression despite little changes in overall mitochondrial morphology [68]. Notably, MFN2 has distinct effects in different cell types. Li et al. demonstrated that its upregulation restores mitochondrial function and reverses senescence in pulmonary cells, whereas Xu et al. found that MFN2 suppression in senescent rat chondrocytes alleviates metabolic-inflammatory cascade [69, 70]. These results suggest that MFN2 regulation is obviously cell-type dependent. This variability may stem from differences in metabolic characteristics, mitochondrial-ER interaction patterns, and stress signaling pathways. In metabolically active cells, such as lung or cardiomyocytes, MFN2 upregulation enhances mitochondrial network connectivity and oxidative metabolic capacity, thereby exerting protective and anti-aging effects. In cells with slow metabolism or susceptible to inflammation (such as chondrocytes), excessive MFN2 activity may disrupt mitochondrial-ER calcium signaling homeostasis or induce a metabolic-inflammatory cascade. Mitochondrial fission and fusion in inflammatory signaling Abnormal mitochondrial fission and fusion can lead to excessive ROS production or mtDNA leakage into the cytoplasm or extracellular environment. These mitochondrial-derived DAMPs serve as critical triggers of inflammatory responses by activating signaling pathways such as the NLRP3 inflammasome, NF-κB and cGAS-STING [71–73] (Fig. 2). This section mainly explores how mitochondrial dynamics imbalance mediates inflammatory signaling through the regulation of key molecular pathways. Integrative illustration of how mitochondrial fission and fusion imbalance drives inflammatory signaling. Phosphorylation of DRP1 promotes mitochondrial fission, while loss of fusion proteins (MFN1/2) impairs mitochondrial connectivity, collectively leading to excessive mtROS generation and mtDNA release. These shared upstream signals converge on multiple inflammatory pathways, including NLRP3 inflammasome, NF-κB, and cGAS-STING signaling, which are functionally interconnected and together exacerbate mitochondrial dysfunction and tissue inflammation. Image created with BioRender.com with permission Canonical inflammatory pathways NLRP3 inflammasome An imbalance between mitochondrial fission and fusion is known to promote NLRP3 inflammasome activation through two interrelated pathways, involving excessive mtROS production and the release of mtDNA. On the one hand, pathological fission mediated by DRP1 disrupts the integrity of ETC. This disruption upregulates respiratory chain proteins, causing mtROS accumulation that drives NLRP3 inflammasome assembly and activation [74]. On the other hand, fragmentation-induced membrane potential collapse or permeability transition triggers mtDNA escape into the cytosol, where the released mtDNA directly binds to NLRP3 to amplify inflammatory cascades [75, 76]. Interestingly, in RNA virus infection models, Mfn2 deficiency unexpectedly suppresses IL-1β secretion through an mtROS-independent mechanism, suggesting that the inflammatory effects of mitochondrial dynamics imbalance are context-dependent [77]. Although some evidence indicates that mtDNA may act as a downstream consequence rather than an initial trigger, it is undeniable that inhibiting mtDNA synthesis can effectively block NLRP3 inflammasome activation, offering novel therapeutic strategies against inflammation [78–80]. Current debates focus on the sequence and relative contributions of mtROS and mtDNA in inflammasome activation. To clarify how mitochondria interact with the inflammasome under different pathological conditions, advanced spatiotemporal imaging and molecular tracking techniques are needed to dissect their regulatory networks. NF-κB pathway Mitochondrial dynamics and the NF-κB pathway are reciprocally regulated. DRP1-mediated excessive mitochondrial fission enhances NF-κB activity through Ser616 phosphorylation, inducing a burst of ROS and driving p65 nuclear translocation [81]. Liver-specific Mfn1 knockout or Dnm1l overexpression in mice further demonstrates that mitochondrial dynamics disturbances exacerbate inflammation and metabolic disorders through ROS-NF-κB positive feedback loops [82]. However, in TNF-α/LPS-induced endothelial inflammation models, the NF-κB subunit p65/RelA is identified as a direct mediator of pathological mitochondrial fission. The classic anti-inflammatory agent salicylate restores mitochondrial homeostasis by suppressing NF-κB activation [83]. Moreover, metabolic regulators such as PGC-1α may further link mitochondrial dynamics with NF-κB activity, revealing a broader coupling between metabolic and inflammatory processes [84]. It is noteworthy that kinases in both the canonical and noncanonical NF-κB pathways also influence mitochondrial dynamics. In the canonical pathway, IKKβ accelerates mitochondrial fragmentation via ubiquitin-dependent degradation of MFN2, while in the noncanonical pathway, NF-κB-inducing kinase modulates DRP1 phosphorylation independently of the IKK complex [85, 86]. Collectively, most studies emphasize the complex feedback network between mitochondrial dynamics and NF-κB activation. However, the prevailing understanding is constrained by evidence from specific stress models or cell types, leaving the causal relationship unclear. Future studies combining genetic, pharmacological, and multi-omics approaches are needed to elucidate whether mitochondrial dynamics act as initiators or amplifiers of NF-κB-driven inflammation. cGAS-STING pathway The imbalance between mitochondrial fission and fusion has been recognized as a key mechanism that activates the cGAS-STING pathway by inducing the release of mtDNA [87, 88]. Downregulation of MFN2 disrupts mitochondrial fusion, leading to mtDNA spillover into the cytosol and subsequent activation of cGAS-STING signaling, a phenomenon observed in post-spinal cord injury inflammation and diabetic myocardial ischemia/reperfusion models [89, 90]. DRP1-dependent fission in LPS-treated Kupffer cells significantly triggers STING signaling through mtDNA release, aggravating murine liver injury [91]. Furthermore, loss of Opa1 compromises cristae integrity and triggers STING-dependent type I interferon responses via mtDNA leakage [92]. In addition to mitochondrial dynamics, aberrant expression of mitochondrial membrane structural proteins contributes to the activation of the cGAS-STING pathway. Deletion of the OMM protein Mitofilin induces cristae damage, causing mtDNA accumulation and cGAS-driven pro-inflammatory transcription, while loss of Vdac1 reduces cytosolic mtDNA levels and suppresses STING phosphorylation [93, 94]. All in all, mitochondrial imbalance activates the cGAS-STING pathway through multiple mechanisms, including mtDNA leakage, membrane collapse, and dysregulated protein interactions. This series of evidence emphasizes that mitochondrial dynamics serves as a core molecular bridge connecting metabolic disorders and the inflammatory storm. AMPK pathway A major role of AMPK in mitochondrial homeostasis is maintaining the balance between mitochondrial fission and fusion [95, 96]. In TNF-α-stimulated fibroblast-like synoviocytes, the AMPK agonist osthole corrects DRP1 upregulation and MFN2 downregulation to restore mitochondrial balance [97]. Similarly, a preclinical study showed that metformin counteracts retinal ischemia/reperfusion-induced imbalance by upregulating MFN2 and OPA1, whereas AMPK inhibition completely abolishes this protective effect [98]. Both animal models and cell experiments have confirmed that the cardioprotective effect of melatonin is highly dependent on OPA1-related mitochondrial fusion, and blocking AMPK affects OPA1 stability and impairs myocardial function [99]. However, AMPK activation is not always beneficial for mitochondrial integrity. In fact, in its phosphorylated state, AMPK can directly regulate mitochondrial dynamics proteins to drive fission. For example, AMPKα phosphorylation at Ser496 recruits DRP1 to the OMM, exacerbating fission through the AMPK-MFF-DRP1 axis [100]. Furthermore, phosphorylation of the AMPK substrate mitochondrial fission regulator 1-like protein induces mitochondrial fragmentation and regulates OPA1 expression, remodeling the mitochondrial network [101]. In summary, these findings suggest that the influence of AMPK on mitochondrial dynamics is not unidirectional but rather determined by both cellular energy status and stress signals. Future studies should focus on elucidating how AMPK signaling cooperates with mitochondrial dynamics to determine cell fate under inflammatory stress. Immune cells phenotypic remodeling Macrophage polarization Mitochondrial dynamics determine macrophage polarization by coupling metabolic reprogramming with inflammatory signaling. In septic acute lung injury, downregulation of SIRT3 increases OPA1 acetylation at lysine 792, leading to mitochondrial imbalance and promoting pro-inflammatory M1 polarization of alveolar macrophages. Restoring the SIRT3-OPA1 deacetylation axis reverses these pathologic changes [56]. Similarly, myeloid-specific Dnm1l deficiency in ischemic peripheral artery disease models suppresses AMPK phosphorylation, enhancing glycolysis and skewing macrophages toward the M1 phenotype while impairing angiogenesis [102]. Anti-inflammatory M2 polarization is dynamically regulated by mitochondrial morphology, with its directionality finely controlled by tissue-specific microenvironments and molecular interaction networks. Luteolin enhances the expression of M2 markers in macrophages by reducing macrophage fission and promoting fusion, thereby alleviating periodontal inflammation and bone loss in a rat model [103]. However, in chronic kidney disease models, progranulin deletion upregulates FIS1 and downregulates MFN2/DRP1 expression, unexpectedly inhibiting M2 polarization and attenuating renal fibrosis, highlighting tissue microenvironment-specific regulation [104]. Notably, pharmacological targeting of mitochondrial dynamics has demonstrated therapeutic potential. Losartan shifts macrophages from M1 to M2 phenotypes by blocking the NF-κB/MAPK pathway, maintaining cardiomyocyte mitochondrial homeostasis and reducing oxidative damage [105]. These findings collectively reveal that mitochondrial fission and fusion integrate metabolic reprogramming, epigenetic modification, and inflammatory signaling to precisely control macrophage polarization, offering novel avenues for metabolic-immunotherapeutic strategies. T cell immunity As central regulators of adaptive immunity, CD4+ and CD8+ T have functional states that depend on mitochondrial dynamics. These dynamics integrate metabolic adaptability and epigenetic programs to shape T cell differentiation, effector function, and exhaustion [106, 107]. For instance, in T helper 17 (TH17) cells, OPA1-mediated mitochondrial fusion is critical for functional integrity by sustaining tricarboxylic acid cycle activity and NADH/NAD+ balance. Opa1 deficiency disrupts these metabolic processes, triggering aberrant glutamine oxidation and epigenetic dysregulation that suppresses TH17 effector function [108]. Likewise, CD8+ T cell fitness relies on mitochondrial homeostasis. OPA1 loss compromises cristae integrity, impairs cell-cycle progression, and constrains metabolic adaptation during effector expansion [109]. Within the tumor microenvironment, glucose deprivation and hypoxia induce DRP1-dependent fission, leading to depolarization and robust mtROS production that synergize with PD-1 signaling to drive tumor-infiltrating CD8+ T cells exhaustion [110]. Additionally, leucine-rich repeat kinase 2 (LRRK2) regulates exhausted CD8+ T cell subset plasticity by phosphorylating DRP1 at Ser637/Ser616, highlighting mitochondrial dynamics as an immunometabolic checkpoint [111]. Overall, imbalances in mitochondrial dynamics reprogram T cell metabolism and epigenetic landscapes, and targeted interventions can restore homeostasis to reverse immune dysfunction, offering novel directions for the treatment of autoimmune diseases. Mitochondrial fission and fusion in inflammatory diseases Dysregulation of mitochondrial dynamics has emerged as a pivotal mechanism underlying numerous inflammation-related pathologies. Persistent cellular stress or inflammatory stimuli trigger excessive mitochondrial fission or impaired fusion, disrupting metabolic homeostasis, promoting ROS generation, and activating inflammatory signaling pathways, ultimately leading to multiorgan tissue damage. This chapter focuses on the organ-specific roles of imbalanced mitochondrial fission and fusion, encompassing systemic disorders ranging from neurodegenerative diseases to cancer, aiming to provide new therapeutic perspectives for targeting mitochondrial dynamics to intervene in chronic inflammation. Neurodegenerative diseases Neurodegenerative diseases are characterized by progressive neuronal loss, accompanied by mitochondrial dysfunction and chronic neuroinflammation. Common diseases include Alzheimer’s disease, Parkinson’s disease, amyotrophic lateral sclerosis, and so on [112]. MacMullen et al. confirmed that mutations in Alzheimer’s disease-related genes disrupt mitochondrial dynamics by promoting fragmentation, resulting in bioenergetic failure and synaptic degeneration [113]. Xi et al. discovered that DRP1 is significantly acetylated and abnormally activated under oxidative stress, exacerbating mitochondrial fragmentation and compromising the mitochondrial function, further promoting the progression of Parkinson’s disease [114]. Similarly, in amyotrophic lateral sclerosis, dephosphorylation of DRP1 at Ser616 driven by protein phosphatase 1 results in excessive mitochondrial fragmentation and impaired respiratory complex I activity, ultimately contributing to motor neuron degeneration [115]. Despite differences in upstream triggers, the resulting imbalance in mitochondrial fission and fusion contributes to impaired energy metabolism and amplified inflammation, ultimately driving neuronal degeneration. Therefore, targeting mitochondrial dynamics may provide therapeutic strategies for restoring neuronal homeostasis and intervening in various neurodegenerative diseases. Cardiovascular diseases The heart, as a high-energy-consuming organ, is vulnerable to disruptions in mitochondrial dynamics, which contribute to cardiovascular pathologies through oxidative stress, inflammatory responses, and impaired mitochondrial quality control [116]. DRP1/FIS1-mediated excessive fission leads to mitochondrial fragmentation and antioxidant capacity loss, whereas enhanced OPA1-dependent fusion restores cristae structure and energy metabolism [117, 118]. Similar fusion-protective effects have also been observed in metabolic stress models, such as brain natriuretic peptide, which attenuates diabetic cardiomyopathy by activating OPA1 [119]. Interestingly, DRP1 exhibits stage-specific regulation in obesity-related cardiomyopathy. Specifically, in the acute phase, DRP1 promotes LC3-dependent conventional mitophagy to clear dysfunctional mitochondria, whereas in the chronic phase, it drives alternative mitophagy by forming a complex with Rab9 and FIS1, although whether sustained activation of this alternative mitophagy pathway leads to mitochondrial dysfunction remains to be elucidated [120]. The mechanistic switch revealed in this study also prompts us to consider that therapeutic strategies targeting mitochondrial dynamics should take different stages of disease into account. Pulmonary diseases The lungs are vital organs for gas exchange, maintaining alveolar cell energy homeostasis through mitochondrial dynamics [121]. Prolonged exposure to insults like cigarette smoke or PM2.5 disrupts the fission-fusion balance, leading to mitochondrial damage, ROS accumulation and increased pro-inflammatory cytokine production, collectively impairing pulmonary function [69, 122]. Similarly, during SARS-CoV-2 infection, the virus triggers a surge in mitochondrial fission and bioenergetic failure, resulting in alveolar epithelial cell apoptosis and contributing to hypoxemia [123]. However, due to our limited understanding of the mechanisms driving dysregulated mitochondrial dynamics in disease states, and the high clinical and pathological heterogeneity of pulmonary diseases, even if they all manifest as excessive mitochondrial fission, the upstream triggering pathways may differ [124]. Therefore, further mechanistic and translational studies are necessary to fully explore the therapeutic potential of mitochondrial network dynamics. Hepatic diseases As a central metabolic organ, the liver’s energy metabolism and redox homeostasis are highly dependent on the dynamic balance between mitochondrial fission and fusion [125]. In non-alcoholic steatohepatitis models, DRP1 overexpression triggers excessive mitochondrial fission and ROS surge, thus promoting hepatic fibrosis [126]. The role of DRP1 in alcoholic hepatitis, however, remains controversial. Palma et al. reported that alcohol exposure upregulates DRP1, leading to mitochondrial fragmentation and damage, whereas Ma et al. observed that alcohol inhibits transcription factor EB-mediated transcription of Dnm1l, reducing DRP1 expression yet still aggravating hepatic inflammation and promoting megamitochondria formation [127, 128]. These contrasting findings suggest that DRP1 expression in the liver may be related to the degree of alcohol exposure, the type of disease, and its own interactions with other signaling factors. Furthermore, Lee et al. experimentally identified that hepatocyte-specific Opa1 knockout disrupts cristae architecture but preserves liver function through the activation of mitohormesis. Remarkably, this adaptation even enhances resistance to drug-induced liver injury, suggesting that the liver has a unique compensatory mechanism that makes it more tolerant to imbalanced mitochondrial dynamics [129]. In conclusion, the hepatic compensatory network partially mitigates the metabolic and structural disturbances caused by dysregulated fission and fusion. This adaptive capacity highlights the liver’s resilience and provides new insights for developing mitochondrial dynamics-targeted therapeutic strategies. Gastrointestinal diseases The intestine is the primary site for nutrient digestion and absorption, and its mucosal epithelial structure serves as a crucial barrier against harmful external stimuli. Mitochondrial fission and fusion regulate cellular metabolism and immune signaling, thereby supporting mucosal integrity and repair capacity [130, 131]. In Escherichia coli-LF82-infected intestinal mucosal epithelial cells, sustained activation of DRP1 and loss of L-OPA1 disrupt mitochondrial connectivity and increase intestinal permeability [132]. Likewise, downregulation of mitochondrial fusion-related genes and mitochondrial network fragmentation have been also observed in crypt intestinal epithelial cells of patients with inflammatory bowel disease [133]. Notably, mitochondria-immune cell crosstalk has been identified as a contributor in the development of intestinal inflammatory diseases. Khan et al. stimulated macrophages with TLR ligands, observing that this enhanced DRP1-dependent mitochondrial fission, which subsequently promoted the production of mtROS and inflammatory factors [134]. Collectively, these findings suggest that mitochondrial dysregulation in intestinal epithelial cells and macrophages represents distinct yet interconnected processes. Understanding this cell-specific crosstalk may help identify new therapeutic strategies to restore intestinal homeostasis. Renal diseases The kidney, an energy-demanding organ with mitochondrial content second only to the heart, relies on precisely coordinated mitochondrial dynamics to sustain metabolic homeostasis [135, 136]. Mitochondrial dynamics are coordinately regulated by multiple signaling pathways. Among them, redox regulatory networks modulate key enzymes such as NOX4 and LRRK2 to control mitochondrial fission and fusion. Deficiency of Nox4 or deletion of Lrrk2 markedly improves the imbalance in mitochondrial dynamics and alleviates renal injury by restoring the expression balance of DRP1, MFN1, OPA1, and MFN2 [137, 138]. Notably, the synergistic interaction between autophagy and mitochondrial dynamics constitutes another core regulatory mechanism. Impaired autophagy triggers a vicious cycle of mitochondrial fragmentation and oxidative damage. For instance, lipocalin-2 disrupts mitochondrial morphology in renal tubules via a DRP1-dependent fission pathway while concurrently activating the mTOR pathway to suppress autophagic clearance, ultimately exacerbating oxidative injury [139]. Consistent with this, inhibition of autophagy itself can induce a self-reinforcing pathological loop through sustained ROS release and mtDNA accumulation [140]. Although current research has revealed that imbalanced mitochondrial dynamics drive nephropathy progression through metabolic-redox-autophagic networks, the specific regulatory mechanisms of mitochondrial dynamics and their stage-specific roles in disease pathogenesis still need to be further analyzed. Joint diseases The inflammatory progression of joint diseases is closely associated with an imbalance between mitochondrial fission and fusion. Meyer et al. discovered that the synovial protein Syntenin-1 activates a co-regulatory mechanism of mitochondrial fusion and fission by simultaneously upregulating MFN2 and DRP1 to meet the high metabolic demands of fibroblast-like synoviocytes. This compensatory reprogramming initially supports cell viability but ultimately exacerbates rheumatoid arthritis under sustained inflammatory stress [141]. In osteoarthritis, mitochondrial translocation of DRP1 induces chondrocyte pyroptosis, while elevated MFN2 similarly leads to cell senescence and inflammation. Therefore, excessive activation of either fission or fusion can disrupt mitochondrial homeostasis and promote the progression of osteoarthritis [35, 70]. Furthermore, in a gouty arthritis model, the deubiquitinating enzyme USP16 mediates the deubiquitination and stabilization of DRP1, enhancing mitochondrial fission and activating NF-κB/NLRP3 pathways [142]. In short, targeting mitochondrial fission and fusion dynamics not only blocks inflammatory signaling but also reprograms cellular energy metabolism, providing a theoretical basis for developing precision therapies against joint diseases. Cancers Chronic inflammation contributes to cancer development by promoting mitochondrial damage and shaping a tumor-supportive microenvironment. Meanwhile, the mitochondrial dynamics play a critical role in metabolic reprogramming and stress adaptation of cancer cells [143]. Hu et al. found that high expression of glutamine transporter SLC6A14 inhibits MFF, thereby driving mitochondrial fusion and oxidative phosphorylation, which further leads to the early onset of breast cancer [144]. Groessl et al. reported that acidosis suppresses the cytoplasmic activity of extracellular signal-regulated kinase, preventing oncogene-induced mitochondrial fragmentation and promoting fused mitochondria. This fused state enhances mitochondrial respiration, supporting energy production and cell survival under nutrient-deprived and acidic conditions. Inhibition of mitochondrial fusion markedly impairs tumor growth in acidic environments [145]. Furthermore, a recent study in Nature revealed that mitochondria divide through fission and fusion to form functionally distinct subpopulations: one enriched in OXPHOS components to sustain ATP supply, and the other enriched in enzymes involved in reductive synthesis. This kinetically dependent division of labor allows cells to simultaneously maintain competing metabolic pathways. Blocking either fusion or fission disrupts subpopulation separation, forcing cells to choose between energy production and reductive synthesis. In pancreatic cancer models, such mitochondrial subpopulation differentiation facilitates tumor cells to adapt to nutrient deprivation and oxidative stress, thereby promoting their survival and proliferation [146]. Overall, mitochondrial fission and fusion support cancer cell survival by regulating metabolic adaptability. However, the specific mechanisms by which these processes contribute to cancer development may vary with tumor type, microenvironmental feature, and stress conditions. Future studies are needed to further elucidate their roles in tumor progression across diverse contexts. Mitochondrial dynamics as emerging therapeutic targets The modulation of mitochondrial dynamics has rapidly emerged as a promising frontier in anti-inflammatory therapy. This progress is driven by a diverse arsenal of pharmacological and technological strategies. This section systematically reviews these approaches, encompassing small-molecule inhibitors and agonists, natural compounds and their bioactive ingredients, genetic manipulation tools, repurposed chemical drugs, and innovative mitochondria-targeted nanoformulations (Table 1). Additionally, we present a schematic illustration (Fig. 3) of the interplay between mitochondrial dynamics, inflammatory signaling, and therapeutic interventions. Table 1Therapeutic compounds targeting mitochondrial dynamics in inflammatory diseasesCategoryCompoundsMechanismPreclinical modelsMain outcomesClinical statusSynthetic inhibitors or activatorsDrpitor1aInhibition of DRP1 GTPase activityHuman hPASMC and BOEC cell models; pulmonary arterial hypertension rat modelReduction of fission; regression of pulmonary arterial hypertension [147]PreclinicalMdivi-1Reduction of DRP1 phosphorylationPatient-derived skin fibroblasts; engineered HEK293T OPA1 knockdown cell modelReduction of fragmentation; restoration of mitophagy balance [148]PreclinicalP110Inhibition of DRP1-FIS1Mouse renal I/R injury model; Bama pig unilateral renal I/R injury model; proximal tubule cell ATP depletion/recovery modelReduction of fragmentation; improvement renal function and histopathology [149]PreclinicalS89Promotion of MFN1-dependent fusionMouse myocardial I/R injury model; oxidative stress and ferroptosis cell modelsIncrease of mitochondrial fusion; alleviation of cardiac I/R injury [150]PreclinicalBGP-15Stabilization the long OPA1 isoformHuman lung tissues; chronic cigarette smoke-exposed mice model; primary fibroblasts and lung cell linesAlleviation of chronic obstructive pulmonary disease [151]PreclinicalS3Increase of non-degradative ubiquitination of MFN1 and MFN2HeLa cell model; WT, Mfn1-/-, Mfn2-/-, Mfn Dko, and OPA1-/mouse embryonic fibroblast modelsIncrease of mitochondrial fusion; restoration of oxidative respiration [152]PreclinicalNatural compoundsArtemetinReduction of DRP1 phosphorylationMouse asthma model; BEAS-2B cell modelInhibition of mitochondrial dysfunction in asthma [153]PreclinicalCrocinMFN2 upregulationOvalbumin-sensitized mouse asthma modelSuppression of allergic airway inflammation [154]PreclinicalNodakeninInhibition of DRP1 phosphorylationMouse knee osteoarthritis model; LPS-stimulated primary chondrocytes modelAttenuation of cartilage degradation and knee osteoarthritis [155]PreclinicalGastrodinActivation of the AMPK-OPA1 pathwaySH-SY5Y oxygen-glucose deprivation/reperfusion model; rat middle cerebral artery occlusion/reperfusion modelEnhancement of fusion; attenuation of cerebral I/R injury [156]PreclinicalKaempferolDownregulation of DRP1, FIS1 and upregulation of MFN1, OPA1Diabetic kidney disease rat model; AGEs-injured HK-2 cell modelRestoration of mitochondrial dynamics and mitophagy [157]PreclinicalChondroitin sulfateDRP1 upregulationHepG2 cells treated with sodium oleate for non-alcoholic steatohepatitis-like modelPromotion of mitochondrial terminal fission and mitophagy [158]PreclinicalChemical drugsEmpagliflozinFIS1 dephosphorylationMouse myocardial I/R injury model, HCAECs sI/R and oxidative stress modelsAlleviation of microvascular and endothelial injury [159]Clinically approved SGLT2 inhibitor; study preclinicalReduction of DRP1, FIS1 and elevation of MFN2, OPA1Acetaminophen-induced acute liver injury model in miceAmelioration of liver inflammation via cGAS/STING suppression [160]Upregulation of MFN1 and OPA1Mouse retinal I/R model, BV2 microglia cell modelAttenuation of neuroinflammation and retinal ganglion cell loss [161]OPA1 upregulationMouse renal I/R model, HK-2 cell hypoxia/reoxygenation modelReduction of renal inflammation [162]DexmedetomidineDRP1, FIS1 downregulation and MFN1, MFN2, OPA1 upregulationMouse sepsis-associated acute lung injury model,NR8383 macrophage cell modelAmelioration of acute lung injury [163]Clinically approved sedative/analgesic; study preclinicalp-DRP1 S616, FIS1 downregulation and MFN1, MFN2, OPA1 upregulationRat sepsis-associated acute kidney injury model, NRK-52E cell modelAmelioration of acute kidney injury [164]SaquinavirDRP1 inhibitionDSS-induced acute or chronic mouse model, isolated mouse intestinal epithelial cells in vitro modelAlleviation of ulcerative colitis via reduction of mitochondrial fission/PANoptosis [165]Clinically approved antiviral drug; study preclinicalLeflunomideStabilization the long OPA1 isoformHuman lung tissues; chronic cigarette smoke-exposed mice model; primary fibroblasts and lung cell linesAlleviation of chronic obstructive pulmonary disease [151]Clinically approved antirheumatic drug; study preclinicalNanoformulationsCsA-TK-SS-31 micelleDownregulation of DRP1, FIS1 and upregulation of MFN1, MFN2, OPA1Alzheimer’s disease mouse model; neuronal/microglial cell modelsAttenuation of neuroinflammation [166]PreclinicalMSNs-MASM7@MI biomimetic nanoparticleMFN2 upregulationSpinal cord injury mouse model; microglia cell modelImprovement of neuronal function recovery; reduction of neuroinflammation [89]PreclinicalNano-selenium SeNPsUpregulation of DRP1, OPA1, MFN1, MFN2Mouse model of microplastic-induced liver injury and hepatocyte culturesProtection against hepatic inflammation [167]PreclinicalMitochondria-targeted kaempferol nanoparticles DTM@KANPsDRP1 upregulationMouse model of severe acute pancreatitis; primary pancreatic acinar cell model under oxidative stressRestoration of mitochondrial fission and mitophagy, mitigation of pancreatic necrosis and inflammation [168]Preclinical Therapeutic compounds targeting mitochondrial dynamics in inflammatory diseases Mouse sepsis-associated acute lung injury model, NR8383 macrophage cell model Schematic illustration of the interplay between mitochondrial dynamics, inflammatory signaling, and therapeutic interventions. Inflammatory stimuli such as LPS, ROS, mtDNA release, and viral infection disrupt the balance between mitochondrial fission and fusion, thereby activating multiple pro-inflammatory pathways, including the NLRP3 inflammasome, NF-κB, and cGAS-STING signaling. These processes contribute to the development of diverse inflammatory diseases, such as neuroinflammation, hepatitis, nephritis, and arthritis. Therapeutic strategies targeting mitochondrial dynamics through inhibitors, activators, natural compounds, genetic interventions, chemical agents, and nanoformulations can restore mitochondrial homeostasis and alleviate inflammation. Image created with BioRender.com with permission Synthetic inhibitors or activators Synthetic compounds targeting mitochondrial dynamics have been widely used in inflammatory treatment research. These compounds regulate key fission and fusion proteins to restore mitochondrial homeostasis while preserving normal function. Small molecule inhibitors of DRP1, such as Drpitor1a and Mdivi-1, reduce excessive fission by suppressing the GTPase activity of DRP1, thereby improve mitochondrial integrity and mitigating inflammatory damage [147, 169]. Peptide inhibitors including P110 and P259 selectively block pathological fission by interfering with the DRP1-FIS1 or DRP1-MFF interactions, respectively [149, 170]. To overcome the pharmacokinetic limitations of peptide drugs, researchers developed a small molecule analog SC9 targeting the DRP1 switch I adjacent groove and verified its efficacy in preclinical models of endotoxemia [171]. Pharmacological activators of fusion-related proteins have also shown therapeutic potential. The MFN2 agonist MASM7 and the MFN1-specific activator S89 effectively restore mitochondrial dynamics balance and alleviate mitochondrial damage, exerting protective effects in models of spinal cord injury and ischemia/reperfusion, respectively [89, 150]. Similarly, the mitochondrial fusion promoter BGP-15 exerts a protective effect by stabilizing the long OPA1 isoform, thus maintaining the structural integrity of mitochondrial cristae. Interestingly, another compound, the diterpenoid derivative S3, facilitates mitochondrial fusion through a different mechanism. Although S3 is an inhibitor of the deubiquitinating enzyme USP30, this inhibition actually enhances the non-degradative ubiquitination of MFN1 and MFN2, ultimately promoting mitochondrial fusion [151, 152]. Natural compounds In addition to synthetic regulators, a growing focus has been on natural compounds, with research increasingly highlighting their therapeutic value through the modulation of mitochondrial dynamics. For example, artemetin and crocin can regulate the expression of DRP1 and MFN2, markedly suppressing asthma or allergic airway inflammation [153, 154]. Nodakenin and ganoderma atrum polysaccharide converge on the mitochondrial DRP1/ROS/NLRP3 axis to mitigate inflammation and tissue injury by reversing excessive mitochondrial fission [155, 172]. Moreover, the phenolic compound gastrodin has been shown to enhance mitochondrial fusion and activate the AMPK-OPA1 pathway, attenuating cerebral ischemia-reperfusion (I/R) injury [156]. Other studies also reveal that compounds such as kaempferol, chondroitin sulfate, and rhapontigenin improve mitochondrial homeostasis via dual modulation of mitochondrial dynamics and mitophagy [157, 158, 173]. Genetic interventions Genetic interventions targeting mitochondrial dynamics, particularly those regulating key factors such as DRP1, MFF, and OPA1, have demonstrated complex yet promising anti-inflammatory potential across various tissues. For instance, partial skeletal muscle-specific knockout of Dnm1l has been shown to enhance whole-body insulin sensitivity and glucose tolerance in diet-induced obese mice [174]. CRISPR/Cas9-mediated depletion of Dnm1l in the nervous system preserves mitochondrial integrity and protects against ferroptosis [175]. Ye et al. provided more direct evidence that intestinal epithelial cell-specific heterozygous knockout of Dnm1l significantly alleviates colitis by inhibiting Z-DNA binding protein 1-dependent PANoptosis [165]. Interestingly, mice lacking Opa1 in the intestinal epithelium (Opa1i∆IEC) spontaneously develop chronic enteritis due to fusion defects and microbial translocation, a phenotype that can be partially rescued by DRP1 inhibitors [133]. Similarly, in the liver, defects in mitochondrial fission also exhibit pro-inflammatory effects. Hepatocyte-specific knockout of either Dnm1l or Mff exacerbates liver injury, including pathological conditions such as alcoholic hepatitis and non-alcoholic fatty liver disease. The underlying mechanisms involve impaired mitophagy, ER stress, infiltration of inflammatory cells, and activation of inflammatory pathways such as cGAS-STING [128, 176, 177]. This phenomenon suggests that the outcomes of genetic interventions in mitochondrial dynamics are remarkably tissue-specific. The fundamental reason likely lies in the intrinsic differences in how various cell types respond to metabolic and stress stimuli arising from an imbalanced mitochondrial network. Chemical drugs In recent years, multiple approved drugs have been reported to exert significant anti-inflammatory effects by regulating mitochondrial dynamics, thereby expanding their potential clinical applications. For example, sodium-glucose cotransporter 2 inhibitors (SGLT2) inhibitors exhibit anti-inflammatory and multi-organ protective effects beyond their hypoglycemic effects [178]. Empagliflozin has been shown to inhibit DRP1/FIS1-mediated mitochondrial fission and promote OPA1/MFN1/MFN2-mediated fusion, thereby counteracting inflammation in various injury models [159–162]. Sotagliflozin, a dual SGLT1/2 inhibitor, also ameliorates mitochondrial fission, enhances Ca2 + buffering capacity, and reduces ROS production in heart failure models, effectively suppressing upstream inflammatory triggers [179]. In addition to this class, other drugs have been found to exhibit anti-inflammatory effects by regulating mitochondrial dynamics. Dexmedetomidine coordinates mitochondrial dynamics balance via the HIF-1α/HO-1 and α2-AR/SIRT1/PGC-1α pathways, mitigating lung and kidney injury in sepsis models [163, 164]. Pioglitazone inhibits DRP1 in an AMPK-dependent manner to alleviate neuroinflammation [180]. Febuxostat reduces oxidative stress and subsequent DRP1 phosphorylation, improving the prognosis of cardiorenal syndrome [181]. And saquinavir can directly inhibit DRP1, inhibit mitochondrial fission-mediated PANoptosis and alleviate ulcerative colitis [165]. Mitochondria-targeted nanoformulations To overcome the off-target effects of conventional drugs, researchers have developed several functionalized nanocarriers that enable the precise delivery of therapeutic agents to mitochondria, thereby correcting the imbalance of mitochondrial dynamics. In the field of neurological disorders, the mitochondria-targeted micelle CsA-TK-SS-31, developed for Alzheimer’s disease, alleviates neuroinflammation by restoring mitochondrial membrane potential and fission-fusion balance [166]. The biomimetic microglial nanoparticle MSNs-MASM7@MI promotes neurological recovery after spinal cord injury through delivering the MFN2 agonist MASM7, which inhibits activation of the cGAS-STING pathway triggered by mtDNA leakage [89]. Similarly, in non-neural organ injuries, the nano-selenium SeNPs has been identified to alleviate microplastic-induced liver inflammation by regulating mitochondrial dynamics in hepatocytes [167]. Notably, nanotechnology has also been employed to enhance the bioavailability of natural compounds. For example, the mitochondria-targeted kaempferol nanoparticle DTM@KANPs effectively suppresses apoptosis and ameliorates severe acute pancreatitis by promoting DRP1-dependent fission and mitochondrial autophagy [168]. Collectively, mitochondria-targeted nanodelivery systems are a promising therapeutic strategy for alleviating mitochondrial dysfunction and inflammatory responses. Further developments in carrier design, biocompatibility, and targeting specificity are crucial for their clinical translation. Remaining challenges and future directions Despite significant progress in understanding mitochondrial dynamics, its clinical translation as a therapeutic target still faces substantial challenges. From a technical standpoint, accurate visualization and functional assessment of mitochondrial dynamics remain difficult. Traditional methods, such as fluorescence microscopy, transmission electron microscopy, and biochemical assays, are constrained by limited resolution, phototoxicity of fluorescent dyes, and heavy dependence on operator expertise [182, 183]. From a translational perspective, the clinical application of mitochondrial dynamics modulators remains hindered by off-target effects, limited organ specificity, and poor bioavailability. Although pharmacological and nanotechnological interventions have shown promise in preclinical models, prolonged modulation of mitochondrial fission or fusion may lead to metabolic imbalance, impaired mitophagy, or tissue-specific dysfunction, highlighting the necessity of comprehensive long-term safety evaluation before clinical translation. Encouragingly, recent technological advances in live-cell imaging, AI-based analysis, and mitochondrial-targeted fluorescent probes have significantly enhanced our ability to quantitatively analyze mitochondrial morphology and bioenergetics. For example, automated image analysis platforms and deep learning-based algorithmic frameworks have enabled high-throughput and unbiased characterization of mitochondrial morphology and network remodeling, providing powerful tools for studying organelle heterogeneity and dynamics [184, 185]. Furthermore, tracking systems based on mtDNA fluorescent labeling and microfluidics have provided new insights into the asymmetric distribution of mitochondrial genetic information and the mechanisms of functional inheritance, laying the foundation for disease-related research [186]. Looking ahead, future research should combine technological innovation with translational strategies to bridge the gap between experimental discovery and clinical application. On the technical front, the integration of advanced imaging, AI-driven analytics, and biomarker-guided monitoring will enable precise and dynamic visualization of mitochondrial behavior in vivo. On the translational side, improving delivery systems to achieve organ- and cell-type-specific targeting, minimizing off-target toxicity, and ensuring pharmacokinetic stability will be essential for clinical advancement. Clinically, therapeutic design should also consider disease stage-specific interventions and long-term safety profiles. Incorporating novel preclinical models such as organoids and inflammation-on-a-chip systems will further enhance mechanistic understanding and predictive accuracy. Ultimately, coordinated progress across technology, pharmacology, and precision medicine will accelerate the transition of mitochondrial dynamics-based therapies from bench to bedside. Acknowledgements This work was supported by the National Natural Science Foundation of China (No. 82074085) and Zhejiang Chinese Medical University Graduate Scientific Research Foundation (No. 2024YKJ15). We extend our appreciation to the Public Platform of Pharmaceutical and Medical Research Center, Academy of Chinese Medical Science, Zhejiang Chinese Medical University for supporting this study. Abbreviations artificial intelligence adenosine 5’-monophosphate-activated protein kinase cyclin-dependent kinase 1 cyclic GMP-AMP synthase-stimulator of interferon genes damage-associated molecular patterns dynamin-related protein 1 endoplasmic reticulum extracellular signal-regulated kinase 1/2 electron transport chain fission 1 protein inner mitochondrial membrane intermembrane space ischemia-reperfusion leucine-rich repeat kinase 2 lipopolysaccharide mitochondrial fission factor mitofusin 1 mitofusin 2 mitochondrial dynamics protein of 49 kDa mitochondrial dynamics protein of 51 kDa neural precursor cell expressed, developmentally down-regulated 4-like nuclear factor-kappaB NOD-, LRR- and pyrin domain-containing protein 3 nicotinamide adenine dinucleotide phosphate oxidase 4 outer mitochondrial membrane optic atrophy 1 oxidative phosphorylation Parkin RBR E3 ubiquitin protein ligase 6-phosphofructo-2-kinase/fructose-2,6-bisphosphatase 3 peroxisome proliferator-activated receptor gamma coactivator 1-alpha PTEN-induced kinase 1 protein kinase A post-translational modifications Rho-associated coiled-coil containing protein kinase 1 sodium-glucose cotransporter 2 inhibitors Sirtuin 3 tripartite motif containing 22 voltage-dependent anion channel Author contributions Wenjing Xu collected information and wrote the original manuscript. Wenjing Xu and Xinru Xu designed and drew the figures. Yaonan Zhang assisted the manuscript preparation. Fenfen Li and Daozong Xia provided guidance and funding. All the authors read and approved the final manuscript. Data availability Not applicable Declarations Ethics approval and consent to participate Not applicable. Consent for publication Not applicable. Competing interests The authors declare that they have no competing interests. Footnotes Publisher’s Note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations. Wenjing Xu and Xinru Xu authors contributed equally to this work. References Associated Data Data Availability Statement Not applicable